Superluminal Medicines raises $60.0M Series B (United States, Sep 2026)
Reach the investors backing rounds like this
Backed by BVF Partners, L.P., Deep Track Capital +6 more · verified emails and LinkedIn on Datapile
Superluminal Medicines Raises $60M Series B to Advance Obesity Drug - Unite.AI
Superluminal Medicines is a biotechnology company using AI and machine learning for drug discovery. They focus on rare genetic forms of obesity and hypothalamic obesity. This Series B funding will advance their lead program for rare genetic forms of obesity toward a first clinical trial.
Superluminal Medicines Raises $60M Series B to Advance Obesity Drug Unite.AI
| Sep 23, 2026 | Ema | $77.0M | Series B | United States |
| Sep 23, 2026 | Baselayer | $35.0M | Series A | United States |
| Sep 23, 2026 | Hubble Network | $200.0M | Series C | United States |
| Sep 23, 2026 | Topdog | $2.5M | Seed | United States |
21,375 investors back startups in United States
You just read who funded Superluminal Medicines. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.